inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 901–1,000 of 1,000
Cui, Z., Dang, G., Song, N., Cui, Y., Li, Z., Zang, X., Liu, H., Wang, Z., & Liu, S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.532371 · Cited by 13
In vitro modeling of isoniazid resistance mechanisms in Mycobacterium tuberculosis H37Rv
Dokrungkoon, T., Tulyaprawat, O., Suwannakarn, K., & Ngamskulrungroj, P. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1171861 · Cited by 13
“Generally, inhA is an enoyl acyl carrier protein reductase that plays a role in mycolic acid synthesis and utilizes NADH as the cofactor (Banerjee et al., 1994; Quemard et al., 1995).”
BackgroundLi, Y., Cai, R.-J., Talbot, E. A., & Wang, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00010-1 · Cited by 11
An update on pathogenesis and management of tuberculosis with special reference to drug resistance
Bhunia, S. K., Sarkar, M., Banerjee, A., & Giri, B. (2015) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(15)60912-4 · Cited by 13
“and others reported that katG-activated INH inhibits inhA (the target for INH), the NADH-dependent enoyl-acyl carrier protein reductase, to interfere with mycolic acid (indispensable element of its cell wall) synthesis[50].”
BackgroundSelf-citationMechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA
McNeil, M. B., Dennison, D. D., Shelton, C. D., Flint, L., Korkegian, A., & Parish, T. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.09.003 · Cited by 12
“Consistent with previous publications, the S94A mutations conferred resistance to INH on solid medium (Table 1) [8,16].”
ResultDimeric benzoboroxoles for targeted activity against Mycobacterium tuberculosis
Guy, C. S., Murray, K. A., Gibson, M. I., & Fullam, E. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob02222h · Cited by 11
Paul, G. K., Mahmud, S., Hasan, M. M., Zaman, S., Uddin, M. S., & Saleh, M. A. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.07.032 · Cited by 12
Huang, Y., Ge, J., Zhang, H., Lei, J.-Q., Zhang, X., & Wang, H. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2005.07.003 · Cited by 11
Tomioka, H. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.1.21 · Cited by 13
Soudani, A., Fredj, S. H., Zribi, M., Messaadi, F., Messaoud, T., Masmoudi, A., Zribi, M., & Fendri, C. (2011) · The Journal of Microbiology · doi:10.1007/s12275-011-0268-1 · Cited by 12
Antimicrobial susceptibility testing of Mycobacterium tuberculosis
Dorbniewski, F. (2002) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2002.00478.x · Cited by 12
Dubnau, E., Soares-Appel, S., Huang, T. J., & Jacobs, W. R. (1996) · Gene · doi:10.1016/0378-1119(95)00841-1 · Cited by 13
Self-citationDaniels, D., Berkes, C. A., Nekoie, A., & Franco, J. (2015) · Journal of Chemical Education · doi:10.1021/ed400891k · Cited by 11
Tuberculosis and the Acquired Immunodeficiency Syndrome
Shaw, R., & Coker, R. (1998) · Springer eBooks · doi:10.1007/978-1-4615-7511-5_8 · Cited by 11
The microbiology of tuberculosis
Levi, M. H. (1995) · Springer eBooks · doi:10.1007/978-1-4899-2869-6_7 · Cited by 11
Pédelacq, J. D., Nguyen, M. C., Terwilliger, T. C., & Mourey, L. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch23 · Cited by 17
Biodegradation of quinolinic acid by a newly isolated bacterium Alcaligenes faecalis strain JQ191
Zhao, L., Jiang, Y., Zhao, Z., Wang, K., Zhang, X., Hong, Q., Qiu, J., & He, J. (2022) · FEMS Microbiology Letters · doi:10.1093/femsle/fnac040 · Cited by 10
Worakitchanon, W., Yanai, H., Piboonsiri, P., Miyahara, R., Nedsuwan, S., Imsanguan, W., Chaiyasirinroje, B., Sawaengdee, W., Wattanapokayakit, S., Wichukchinda, N., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.10.004 · Cited by 14
Proteomic characterization of Mycobacterium tuberculosis subjected to carbon starvation
Devlin, K. L., Leach, D. T., Stratton, K. G., Lamichhane, G., Lin, V., & Beatty, K. E. (2025) · mSystems · doi:10.1128/msystems.01530-24 · Cited by 14
Maleki, M. R. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s542287 · Cited by 13
An IPTG Inducible Conditional Expression System for Mycobacteria
Ravishankar, S., Ambady, A., Ramu, H., Mudugal, N. V., Tunduguru, R., Anbarasu, A., Sharma, U. K., Sambandamurthy, V. K., & Ramaiah, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134562 · Cited by 10
“InhA and RpoB proteins are the molecular targets of the front line TB drugs, isoniazid and rifampicin, respectively [36, 37].”
BackgroundDavoodi, S., Daryaee, F., Iuliano, J. N., Collado, J. T., He, Y., Pollard, A. C., Gil, A. A., Aramini, J. M., & Tonge, P. J. (2023) · Biochemistry · doi:10.1021/acs.biochem.2c00606 · Cited by 10
Unissa, A. N., & Elizabeth, H. L. (2014) · Tuberculosis · doi:10.1016/j.tube.2014.08.011 · Cited by 10
Ren, J.-X., Qian, H., Huang, Y., Zhu, N., Si, S., & Xie, Y. (2015) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2014.12.020 · Cited by 10
Neckles, C., Pschibul, A., Lai, C., Hirschbeck, M. W., Kuper, J., Davoodi, S., Zou, J., Liu, N., Pan, P., Shah, S., et al. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01301 · Cited by 10
da Costa, T. P. S., Nanson, J. D., & Forwood, J. K. (2017) · Scientific Reports · doi:10.1038/srep39277 · Cited by 10
Dixit, S. R., Joshi, S. D., Kulkarni, V. H., Jalalpure, S. S., Kumbar, V., Mudaraddi, T. Y., Nadagouda, M. N., & Aminabhavi, T. M. (2017) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501711010092 · Cited by 10
Moreno-Molina, M., Comas, I., & Furió, V. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.01.013 · Cited by 11
Velappan, A. B., Datta, D., Ma, R., Rana, S., Ghosh, K. S., Hari, N., Franzblau, S. G., & Debnath, J. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104170 · Cited by 11
Gausi, K., Chirehwa, M., Ignatius, E. H., Court, R., Sun, X., Moran, L. E., Hafner, R., Wiesner, L., Rosenkranz, S. L., Jager, V. R. D., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac188 · Cited by 10
Defining mycobacteria: Shared and specific genome features for different lifestyles
Vissa, V., Sakamuri, R. M., Li, W., & Brennan, P. J. (2009) · Indian Journal of Microbiology · doi:10.1007/s12088-009-0006-0 · Cited by 12
Quémard, A., Mazères, S., Sut, A., Lanéelle, G., & Lacave, C. S. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)00174-w · Cited by 10
QSAR analysis of B-ring-modified diaryl ether derivatives as a InhA inhibitors
Jain, A. K., Veerasamy, R., Vaidya, A., Kashaw, S. K., Mourya, V. K., & Agrawal, R. K. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9518-8 · Cited by 10
“Mycobacterium gene inhA encoded NADH-dependent enoyl-ACP reductase is a primary molecular target of the frontline antitubercular drug isoniazid (INH) ( Banerjee et al., 1994 ).”
BackgroundInfluentialShivashekaregowda, N. K. H., Parumasivam, T., Ibrahim, P., Asmawi, M. Z., & Sadikun, A. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0715-0 · Cited by 11
“The resulting INH-NAD adduct later inhibits enzyme enoyl–acyl carrier protein reductase (InhA) (Banerjee et al., 1994; Quemard et al., 1995), an enzyme of the fatty acid synthase type II (FAS II) complex, involved in the mycolic acid synthesis (central constituents H.”
BackgroundIdentification of the anti‐mycobacterial functional properties of piperidinol derivatives
Guy, C. S., Tichauer, E., Kay, G. L., Phillips, D. J., Bailey, T. L., Harrison, J., Furze, C. M., Millard, A. D., Gibson, M. I., Pallen, M. J., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13744 · Cited by 10
“, 2012) that is involved in the export of trehalose monomycolate and cell wall biosynthesis, and InhA, an enoyl-acyl carrier protein reductase that is a key component in the type II fatty acid synthase system (FasII) and is the cellular target for isoniazid (Banerjee et al., 1994).”
Complex multifractal nature in Mycobacterium tuberculosis genome
Mandal, S., Roychowdhury, T., Chirom, K., Bhattacharya, A., & Singh, R. K. B. (2017) · Scientific Reports · doi:10.1038/srep46395 · Cited by 12
“Drug resistant genes such as rpoB 23,24 , inhA 25 , katG 26 , gyrA 27 , ahpC 28 , embB 29 , pncA 30 have been experimentally identified.”
Zhou, Y.-C., He, S.-M., Wen, Z.-L., Zhao, J.-W., Song, Y.-Z., Zhang, Y., & Zhang, S.-L. (2020) · Laboratory Medicine · doi:10.1093/labmed/lmaa016 · Cited by 11
Rapid Detection of Resistance Associated Mutations in Mycobacterium tuberculosis by LightCycler PCR
Torres, M. J., Criado, A., Palomares, J. C., & Aznar, J. (2002) · Springer eBooks · doi:10.1007/978-3-642-48351-6_7 · Cited by 10
Antibacterials - mechanisms of action
Piddock, L. J. V. (1998) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(98)80081-7 · Cited by 10
Molecular approaches to tuberculosis
Aínsa, J. A., Martín, C., & Gicquel, B. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02652.x · Cited by 10
“smegmatis as the product of the inhA gene, an enzyme similar to NADH-specific enoyl ACP reductase (Banerjee et al., 1994), indicating that KatGactivated isoniazid probably reacts with NADH to form adduct which binds and inactivates InhA.”
BackgroundNAT2 Polymorphisms and their Influence on the Pharmacology and Toxicity of Isoniazid in TB Patients
Werely, C. J., Donald, P. R., & van Helden, P. D. (2007) · Personalized Medicine · doi:10.2217/17410541.4.2.123 · Cited by 12
Chapter 17. Recent Advances in the Chemistry and Biology of Anti-mycobacterial Agents
Baker, W. R., Mitscher, L. A., Arain, T. M., Shawar, R. M., & Stover, C. K. (1996) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60456-x · Cited by 10
Jang, K., Pierotti, D., Kemp, G. W., Best, G. R., & Britz, M. L. (1997) · Microbiology · doi:10.1099/00221287-143-10-3209 · Cited by 10
Sensi, P., & Grassi, G. G. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc089 · Cited by 11
Bhaskar, V., Kumar, S., Nair, A. S., Gokul, S., Krishnendu, P. R., Benny, S., Amrutha, C., Manisha, D. S., Bhaskar, V., Zachariah, S. M., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2291549 · Cited by 9
“The M. tuberculosis NADH-dependent ACP reductase enzyme catalyzes the transfer of the 4 S hydrogen of NADH co-factor to 3 rd carbon of long chain enoyl thioester substrates, yielding NAD þ and acyl-ACP(CoA) (Quemard et al., 1995), and has reported to be the proposed target of INH (Banerjee et al., 1994; Bhaskar et al.…”
InfluentialIs Mycobacterial InhA a Suitable Target for Rational Drug Design?
Rizet, J., Maveyraud, L., Rengel, D., Guillet, V., Publicola, G., Rodriguez, F., Lherbet, C., & Mourey, L. (2025) · ChemMedChem · doi:10.1002/cmdc.202500079 · Cited by 9
Эргешов, А. Э., Andreevskaya, S. N., Ларионова, Е. Е., Смирнова, Т. Г., & Черноусова, Л. Н. (2017) · Molecular Biology · doi:10.1134/s0026893317030049 · Cited by 9
Schaaf, H. S., Seddon, J. A., & Caminero, J. A. (2011) · Progress in respiratory research/Progress in research in emphysema and chronic bronchitis/Progress in respiration research · doi:10.1159/000324382 · Cited by 10
Gunasekaran, S., Rajalakshmi, K. V., & Kumaresan, S. (2013) · Indian Journal of Physics · doi:10.1007/s12648-013-0309-1 · Cited by 9
Kumar, A., & Siddiqi, M. I. (2009) · Journal of Molecular Modeling · doi:10.1007/s00894-009-0584-0 · Cited by 9
“Studies over the years have established that MtENR is the primary molecular targets of INH [2], the drug that for the past 40 years has been, and continues to be, the frontline agent for the treatment of TB.”
BackgroundMathew, B., Mathew, G. E., Sonia, G., Kumar, A., Charles, N. P., & Kumar, P. S. (2013) · Bangladesh Journal of Pharmacology · doi:10.3329/bjp.v8i3.14778 · Cited by 9
REMap: Operon map of M. tuberculosis based on RNA sequence data
Pelly, S., Winglee, K., Xia, F., Stevens, R. L., Bishai, W. R., & Lamichhane, G. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.04.010 · Cited by 10
“Both these operons have been determined through genome conservation, genetic manipulation and functional studies of the loci[29,30], but lack co-transcription data of all genes within the operons.”
Marine Macrolides to Tackle Antimicrobial Resistance of Mycobacterium tuberculosis
Mamada, S. S., Nainu, F., Masyita, A., Frediansyah, A., Utami, R. N., Salampe, M., Emran, T. B., Lima, C. M. G., Chopra, H., & Simal‐Gándara, J. (2022) · Marine Drugs · doi:10.3390/md20110691 · Cited by 10
Mycolic Acid/Cyclopropane Fatty Acid/Fatty Acid Biosynthesis and Health Relations
Kastrinsky, D. B., McBride, N. S., Backus, K. M., LeBlanc, J. J., & Barry, C. E. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00029-0 · Cited by 11
Activity of Twelve Second-Line Antimicrobial Agents AgainstMycobacterium tuberculosisin Taiwan
Lu, P., Peng, C., Hwang, J.-J., & Chen, Y. (2008) · Journal of Chemotherapy · doi:10.1179/joc.2008.20.2.202 · Cited by 9
Belardinelli, J. M., & Morbidoni, H. R. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.24 · Cited by 10
Li, Q., Fu, T., Li, C., Fan, X., & Xie, J. (2016) · RSC Advances · doi:10.1039/c6ra07733a · Cited by 12
Tanigawa, K., Hayashi, Y., Hama, K., Yamashita, A., Yokoyama, K., Luo, Y., Kawashima, A., Maeda, Y., Nakamura, Y., Harada, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249184 · Cited by 9
“Medications such as isoniazid, ethionamide, isoxyl and thiacetazone that inhibit mycolic acid synthesis have shown antimycobacterial effects [43, 44].”
BackgroundWang, H., Liu, L., Lü, Y., Pan, P., Hooker, J. M., Fowler, J. S., & Tonge, P. J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.019 · Cited by 9
Broussy, S., Bernardes‐Génisson, V., Coppel, Y., Quémard, A., Bernadou, J., & Meunier, B. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b417698g · Cited by 10
Lee, I.-H., Kim, E.-J., Cho, Y.-H., & Lee, J. K. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02702-x · Cited by 9
Duncan, K. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.2.129 · Cited by 10
Hallmarks of mycolic acid biosynthesis: A comparative genomics study
Raman, K., Rajagopalan, P., & Chandra, N. R. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21591 · Cited by 9
Mycobacterial virulence factors
Gordon, S. V., & Andrew, P. W. (1996) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.1996.tb04828.x · Cited by 9
Understanding the key challenges in tuberculosis drug discovery: what does the future hold?
Zein-Eddine, R., Ramuz, M., Refrégier, G., Lutzeyer, J. F., Aleksandrov, A. V., & Myllykallio, H. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2531229 · Cited by 11
Common Biological Properties of Mycobacterium tuberculosis MmpL3 Inhibitors
Ames, L., Allen, R. H., Boshoff, H. I., Cleghorn, L. A. T., Engelhart, C. A., Schnappinger, D., & Parish, T. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00394 · Cited by 9
Mutation-based mechanisms of antibiotic resistance
Misra, R. (2026) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00101-25 · Cited by 11
Haddoumi, G. E., Mansouri, M., Bendani, H., Bouricha, E. M., Kandoussi, I., Belyamani, L., & Ibrahimi, A. (2023) · Advances and Applications in Bioinformatics and Chemistry · doi:10.2147/aabc.s394535 · Cited by 10
Zhang, Q., Han, J., Zhu, Y., Yu, F., Hu, X., Tong, H. H. Y., & Liu, H. (2023) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-023-00530-4 · Cited by 8
“Studies have proposed InhA as the target [10, 11] of the anti-TB pro-drugs isoniazid and ethionamide, which are first activated by the KatG and EthA enzymes, respectively, and then inhibit the reduction of the substrate by forming adducts with NADH [12].”
BackgroundMtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
Boshoff, H. I., Young, K., Ahn, Y., Yadav, V. D., Crowley, B. M., Yang, L., Su, J., Oh, S., Arora, K., Andrews, J., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00025 · Cited by 8
Vadankula, G. R., Nilkanth, V. V., Rizvi, A., Yandrapally, S., Agarwal, A., Chirra, H., Biswas, R., Arifuddin, M., Nema, V., Alvala, M., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00277 · Cited by 8
Design and development of pyrrole carbaldehyde: an effective pharmacophore for enoyl-ACP reductase
Joshi, S. D., Kumar, D., More, U. A., Yang, K. S., & Aminabhavi, T. M. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1517-y · Cited by 8
“Among these, fatty acid biosynthesis-I (FabI) constitutes a single isoform in the majority of pathogens such as Staphylococcus aureus (Heath et al., 2000), Escherichia coli (Heath and Rock, 1995) and M. tuberculosis (Banerjee et al., 1994).”
BackgroundMethodUnissa, A. N., Dusthackeer, A., Kumar, M. P., Nagarajan, P., Sukumar, S., Kumari, V. I., Lakshmi, A. R., & Hanna, L. E. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.07.014 · Cited by 8
Eltschkner, S., Kehrein, J., Le, T. A., Davoodi, S., Merget, B., Basak, S., Weinrich, J. D., Schiebel, J., Tonge, P. J., Engels, B., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00437 · Cited by 9
“The mycobacterial ENR, known as InhA, has been recognized as the prime target of activated isoniazid, the front-line drug against TB [13], whereas various inhibitors of the S.”
BackgroundHuang, S., Zhou, W., Tang, W., Zhang, Y., Hu, Y., & Chen, S. (2021) · BMC Genomics · doi:10.1186/s12864-021-07572-8 · Cited by 9
Callum, J., Nguyen, P. T. B., Martinez, E. M., Nguyen, V.-A. T., Garden, F. L., Nhung, N. V., Nguyen, T. A., Nguyen, H. B., Nguyen, S. V., Luu, K. B., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00122-2022 · Cited by 8
Désire, I., Cyrille, B., Djigma, F. W., Diandé, S., Yonli, A. T., Jean, B., Compaore, T. R., Gnoula, C., Djibril, T., Moret, R., et al. (2015) · Pan African Medical Journal · doi:10.11604/pamj.2015.21.73.5494 · Cited by 10
“Les mutations dans inhA ne provoquent pas seulement la résistance à l'isoniazide, mais elles confèreraient également une résistance croisée à l'égard d'un médicament structurellement proche, tel que l'éthionamide [22].”
Navigating tuberculosis drug discovery with target-based screening
Miller, C. H., & O’Toole, R. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586999 · Cited by 10
“This occurs through adduct binding and inhibition of InhA (ENR) [91] which catalyzes the final enzymatic step in the elongation cycle of the type II fatty acid biosynthetic pathway (FAS-II) [92].”
BackgroundLee, J. H., Kim, B. H., & Lee, M. (2014) · Annals of Clinical Microbiology · doi:10.5145/acm.2014.17.3.115 · Cited by 9
Richner, S. M., Meiring, J., & Kirby, R. (1997) · Electrophoresis · doi:10.1002/elps.1150180915 · Cited by 8
Brossier, F., Cambau, E., Tessier, E., Jarlier, V., & Sougakoff, W. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.09.028 · Cited by 8
“ETH and INH both target the enzyme InhA involved 25 in the cell wall biosynthesis [2].”
BackgroundHassan, S., Sudhakar, V., Mary, M. B. N., Babu, R., Doble, M., Dadar, M., & Hanna, L. E. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1615987 · Cited by 8
Moorey, A. R., Cabanillas, A., Batt, S. M., Ghidelli, S., Urones, B., Sanz, O., Lelièvre, J., Bantscheff, M., Cox, L. R., & Besra, G. S. (2021) · The Cell Surface · doi:10.1016/j.tcsw.2021.100068 · Cited by 8
Rapid diagnosis of tuberculosis. Detection of drug resistance mechanisms
Viñuelas‐Bayón, J., Vitoria, M. A., & Samper, S. (2017) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2017.08.009 · Cited by 8
Vilchèze, C., & Jacobs, W. R. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch22 · Cited by 14
Self-citationNguyen, M., Quémard, A., Marrakchi, H., Bernadou, J., & Meunier, B. (2001) · Comptes Rendus de l Académie des Sciences - Series IIC - Chemistry · doi:10.1016/s1387-1609(00)01180-4 · Cited by 9
Poletto, S. S., da Fonseca, I. O., de Carvalho, L. P. S., Basso, L. A., & Santos, D. S. (2003) · Protein Expression and Purification · doi:10.1016/j.pep.2003.10.009 · Cited by 8
Köser, C. U., Veerapen-Pierce, R. N., Summers, D. K., & Archer, J. A. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00422-10 · Cited by 8
Autio, K. J. (2007) · Cited by 8
Kundu, J., Verma, A., Verma, I., Bhadada, S. K., & Sharma, S. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100997 · Cited by 8
“Mycobacteria have intrinsically developed the ability to resist and degrade these antimicrobial agents [29,30].”
BackgroundPatel, V. P., Tripathi, R. K. P., & Dharamsi, A. T. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099333313240909103833 · Cited by 8
Makhoba, X. H., & Krysenko, S. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030032 · Cited by 7
“Mycobacterial membrane proteins have been recognized as potential drug targets in M. tuberculosis , the inhibition of which can be achieved using the drugs SQ109, NITD-304, NITD-349, and BM212/BM635 [89].”
Prakash, C., Pandey, M., Talwar, S., Singh, Y., Kanojiya, S., Pandey, A. K., & Kumar, N. (2020) · Biochimie · doi:10.1016/j.biochi.2020.08.007 · Cited by 8
Xu, S., Jiang, Y., Zhang, F., Wang, X., Zhang, K., Zhao, L., Hong, Q., Qiu, J., & He, J. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.02390-21 · Cited by 9
Pappachen, L. K., Bhaskar, V., Kumar, S., Nair, A. S., Krishnendu, P. R., Sudevan, S. T., Parambi, D. G. T., Al-Sehemi, A. G., & Zachariah, S. M. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220415144511 · Cited by 8
Bell, A. F., Stratton, C. F., Zhang, X., Novichenok, P., Jaye, A. A., Nair, P. A., Parikh, S. L., Rawat, R., & Tonge, P. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068219m · Cited by 7
Chang, K. C., Yew, W., & Zhang, Y. (2009) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050802665694 · Cited by 8
Usha, V., Dover, L. G., Roper, D. I., Lloyd, A. J., & Besra, G. S. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00356.x · Cited by 7
“tuberculosis cell wall has provided good cellular targets for the development of anti-tuberculosis drugs (Takayama et al., 1979; Kilburn & Takayama, 1981; Quemard et al., 1991; Banerjee et al., 1994; Larsen et al., 2002).”
BackgroundResultLópez-Lara, I. M., & Geiger, O. (2018) · Springer eBooks · doi:10.1007/978-3-319-43676-0_5-1 · Cited by 7
“1998), and isoniazid is an antituberculosis drug that inhibits InhA, the homologue to FabI from Mycobacterium tuberculosis involved in mycolic acid biosynthesis (Banerjee et al. 1994).”
BackgroundPimentel, A. L., Scodro, R. B. D. L., Caleffi-Ferracioli, K. R., Siqueira, V. L. D., Campanerut‐Sá, P. A. Z., Lopes, L. D. G., de Almeida, A. L., Cardoso, R. F., & Seixas, F. A. V. (2017) · Journal of Molecular Modeling · doi:10.1007/s00894-017-3290-3 · Cited by 7
“INH is one of the oldest known synthetic antitubercular drugs [2] and is considered a prodrug, which targets the catalase-peroxidase (KatG) of the bacteriumMycobacterium tuberculosis in such a way that it is converted to an active metabolite, acting against the bacillus only at the active replication stage [3].”
Background
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.